The Alzheimer center of the VU University Medical Center opened in 2000 and was initiated
to combine both patient care and research. Together, to date, all patients forming the …

Objective To investigate the relationship between the ATN classification system (amyloid,
tau, neurodegeneration) and risk of dementia and cognitive decline in individuals with …

Purpose To review how outcomes of clinical utility are operationalized in current amyloid-
PET validation studies, to prepare for formal assessment of clinical utility of amyloid-PET …

Background and Objectives Multiple biomarkers have been suggested to measure
neurodegeneration (N) in the AT (N) framework, leading to inconsistencies between studies …

Background and Objectives β-amyloid (Aβ) staging models assume a single spatial-
temporal progression of amyloid accumulation. We assessed evidence for Aβ accumulation …

Alzheimer's disease is a heterogeneous disorder. Understanding the biological basis for this
heterogeneity is key for developing personalized medicine. We identified atrophy subtypes …

BACKGROUND Low cerebrospinal fluid (CSF) amyloid-β 1–42 (Aβ 1–42) concentrations
indicate amyloid plaque accumulation in the brain, a pathological hallmark of Alzheimer …

Importance Previous studies have evaluated the diagnostic effect of amyloid positron
emission tomography (PET) in selected research cohorts. However, these research …

Background: The recent COVID-19 pandemic is not only a major healthcare problem in
itself, but also poses enormous social challenges. Though nursing homes increasingly …

Objective To develop and evaluate a model for staging cortical amyloid deposition using
PET with high generalizability. Methods Three thousand twenty-seven individuals (1,763 …